Eton Pharmaceuticals Files 8-K on Shareholder Votes
Ticker: ETON · Form: 8-K · Filed: Jun 11, 2024 · CIK: 1710340
Sentiment: neutral
Topics: corporate-governance, filing, shareholder-vote
Related Tickers: ETON
TL;DR
Eton Pharma (ETON) filed an 8-K for shareholder votes - standard governance stuff.
AI Summary
Eton Pharmaceuticals, Inc. filed an 8-K on June 11, 2024, to report on matters submitted to a vote of its security holders. The filing details the company's corporate structure, including its state of incorporation (Delaware) and fiscal year end (December 31).
Why It Matters
This filing indicates that Eton Pharmaceuticals is engaging in corporate governance activities requiring shareholder approval, which is a standard but important part of operating as a public company.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain any new material risks or negative developments.
Key Numbers
- 001-38738 — SEC File Number (Identifies the company's filing history with the SEC.)
- 37-1858472 — I.R.S. Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 2024-06-11 (date) — Date of Report
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote, but the specific details of these matters are not provided in the excerpt.
When was the earliest event reported in this filing?
The earliest event reported is June 11, 2024, which is also the date of the report.
What is Eton Pharmaceuticals' principal executive office address?
The principal executive offices are located at 21925 W. Field Parkway, Suite 235, Deer Park, Illinois 60010-7208.
What is Eton Pharmaceuticals' telephone number?
The company's telephone number is (847) 787-7361.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 572 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-06-11 16:18:06
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
Filing Documents
- eton20240606_8k.htm (8-K) — 33KB
- 0001437749-24-019953.txt ( ) — 165KB
- eton-20240611.xsd (EX-101.SCH) — 3KB
- eton-20240611_def.xml (EX-101.DEF) — 12KB
- eton-20240611_lab.xml (EX-101.LAB) — 15KB
- eton-20240611_pre.xml (EX-101.PRE) — 12KB
- eton20240606_8k_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders The 2024 Annual Meeting of Stockholders (the "Annual Meeting") of Eton Pharmaceuticals, Inc. (the "Company") was held virtually on June 11, 2024. At the meeting, the Company's stockholders (1) elected the director nominees Norbert G. Riedel and Sean E. Brynjelsen for a three-year term, (2) approved, on an advisory basis, the compensation of the Company's named executive officers, (3) voted for, on an advisory basis, annual voting on executive compensation, and (4) ratified the appointment of KMJ Corbin & Company LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024. The results for each of the matters voted upon by the Company's stockholders at the Annual Meeting were as follows: Proposal 1: Election of Directors Nominee For Against Abstain Broker Non-Votes Norbert G. Riedel 8,823,386 954,567 9,293 7,579,711 Sean E. Brynjelsen 9,666,679 118,185 2,382 7,579,711 Proposal 2: Advisory Vote to Approve Executive Compensation For Against Abstain Broker Non-Votes 9,170,839 553,043 63,364 7,579,711 Proposal 3: Advisory Vote on the Frequency of Votes on Executive Compensation 1 Year 2 Years 3 Years Abstain 6,169,483 45,500 3,545,483 26,780 Proposal 4: Ratification of the Appointment of KMJ Corbin & Company LLP as the Company ' s Independent Registered Public Accounting Firm for the year ending December 31, 2024 For Against Abstain Broker Non-Votes 17,193,502 150,140 23,315 0 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 11, 2024 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 3